Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Ovid and Angelini Pharma have announced an agreement in which Angelini will be responsible to develop, manufacture and commercialize OV101 (gaboxadol).
read more
Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 for the potential treatment of Angelman syndrome.
read more
Ovid Therapeutics announced a strategic research collaboration with Columbia University Irving Medical Center researchers to advance genetic based therapies for a range of rare neurological conditions.
read more
Wednesday, August 12, 2020
CluePoints announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials.
read more
Wednesday, November 06, 2013
The strategies and timing of outsourcing pharmaceutical development processes to a contract testing laboratory will be the focus of a mini-workshop at the 2013 AAPS Annual Meeting and Exposition on Nov. 12, 2013.
read more
Tuesday, October 11, 2022
The Outsourcing Facilities Association (OFA) announced that it has reached a settlement agreement with the FDA that spurs the FDA to promptly review long-pending nominations for active pharmaceutical ingredients for use by FDA-registered outsourcing ...
read more
The current global discovery outsourcing market of cancer immunotherapy is about $2.8 B. In the past five years (2010 - 2014), its CAGR was about 37%. Based on analysis, Research and Markets forecast that the global cancer immunotherapy-focused drug ...
read more
Friday, December 22, 2017
Otsuka Pharmaceutical and X-Chem have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.
read more
Otonomy announced a license agreement with KYORIN that provides exclusive worldwide rights to develop, manufacture and commercialize a novel compound for sensorineural hearing loss.
read more
Thursday, February 21, 2013
OsoBio President Milton Boyer will serve on a panel of experts examining shortages of injectable pharmaceuticals during DCAT Week.
read more
Friday, December 20, 2013
OsoBio has reaffirmed its long-standing partnership with the Drug, Chemical and Associated Technologies Association (DCAT) by accepting new volunteer leadership positions within the organization.
read more
As part of OsoBio’s quality control department, the microbiology and chemistry laboratories that Larese now directs are responsible for environmental monitoring, analytical method development, and testing all incoming raw materials, components, and ...
read more
OsoBio has named Lindsey Pruitt manager of new business development for its East Coast market.
read more
OsoBio has named David M. Lee vice president of quality. Lee is responsible for overseeing all quality-related functions to ensure the company’s
continued compliance with Current Good Manufacturing Practices (cGMP), including quality
systems, ...
read more
Wednesday, April 02, 2014
OsoBio has appointed Catherine R. Buck director of manufacturing. In her capacity, Buck is responsible for ensuring that OsoBio’s operations comply with current Good Manufacturing Practices (cGMP) as they apply to the manufacturing of injectable ...
read more